Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

July 22, 2022

Study Completion Date

March 24, 2025

Conditions
Advanced Gastric Cancer
Interventions
DRUG

Camrelizumab

Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.

DRUG

Apatinib Mesylate

Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。

DRUG

nab-paclitaxel

nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.

DRUG

S1

S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time

Trial Locations (1)

350000

Fujian Medical University Union Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT04195828 - Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter